Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

A. Buisson (1) , M. Nachury (2) , Mathurin Fumery (3, 4) , T. Guilmoteau , E. Leclerc (5) , R. Altwegg (6) , M. Serrero , N. Mathieu , X. Treton (7) , L. Vuitton (8) , B. Pereira (1) , A. Amiot (9) , G. Bouguen (10, 11)

1 CHU Clermont-Ferrand
2 Hôpital Claude Huriez [Lille]
3 CHU Amiens-Picardie
4 PERITOX - Périnatalité et Risques Toxiques - UMR INERIS_I 1
5 IRCELYON - Institut de recherches sur la catalyse et l'environnement de Lyon
6 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
7 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
8 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
9 CHU Henri Mondor
10 CIC - Centre d'Investigation Clinique [Rennes]
11 CHU Pontchaillou [Rennes]

Domaines: Sciences du Vivant [q-bio]

A. Buisson, M. Nachury, Mathurin Fumery, T. Guilmoteau, E. Leclerc, et al.. Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent. Journal of Crohn's and Colitis, 2022, 16 (1), pp.I120. ⟨hal-03665871⟩